Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

CARBAGLU (carglumic acid)

GPI CODING:

30908230000320

DESCRIPTION:

Carbaglu acts as a replacement for the compound N-acetylglutamate (NAG), which is lacking in patients with deficiency of the enzyme NAG synthase. NAG synthase is one of several enzymes that help to break down nitrogen and remove ammonia from the body. Carbaglu is FDA-approved for acute treatment of hyperammonemia and for maintenance treatment of chronic hyperammonemia in patients with NAG synthase deficiency. Carbaglu may also be used for treating methylmalonic acidemia and propionic acidemia.

APPROVAL DURATION:

Approval duration: 1 year

CRITERIA FOR CARBAGLU

I. Patient has a diagnosis of NAG synthase deficiency **AND**
II. The diagnosis was confirmed by enzyme analysis or genetic testing **OR**
III. Patient has a diagnosis of methylmalonic acidemia **OR**
IV. Patient has a diagnosis of propionic acidemia